News 2021-04-21
2021 Pharmaceutical Crystallization Summit
Breaking Drug Development Bottlenecks via Enabling Technologies
Physical & chemical properties of drug substance (DS) have major impacts on the formulation process & Drug Product (DP) properties or quality attributes. The final step in an API synthesis is usually crystallization or precipitation, serving as both purification and isolation. This international conference gathers industrial and academic subject matter experts to discuss their works related to DS crystallization and manufacturing opportunities （highlighted below）for new drug development programs.
(1) crystal structure prediction, (2) crystal shape prediction, (3) solubility assessment, (4) purification, and (5) analytical technologies
(1) co-processed API’s, (2) process intensification, (3) additive manufacturing, (4) adv. process control & automation, (5)modular systems
Please Click the image below to see more details.
Others
More
News 2026-09-17
Porton Congratulates Partner Acepodia on FDA and NMPA IND Approvals for ACE723, a Dual-Payload ADC
This project demonstrates Porton's process-development and scale-up capabilities for complex conjugates and adds to its experience supporting innovative biopharma companies worldwide.
News 2026-09-15
Porton Chongqing Liangjiang Drug Product Manufacturing Site Earns Recertification of ISO 14001 & ISO 45001
This successful recertification highlights the standardized operation of the site's management systems, the rigor of its on-site management, and the robustness of its risk control mechanisms, further validating the continued effectiveness of the dual systems.
